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Abstract 
Background Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases. Few data are 
available on the prevalence and the factors associated with mild inflammatory bowel diseases (IBD).  
Aim Our aim was to assess the natural history of mild CD and mild UC and to identify predictive factors of mild 
evolution over the long term.  
Methods Retrospective study of IBD patients registered in the database of the university hospital CHU of Liège, 
Belgium. Mild CD was defined as an inflammatory luminal disease (no stricture, abdominal or perianal fistulae) 
requiring no immunomodulator (IM), anti-TNF and no surgery. Mild UC was defined as no requirement for IM, 
anti-TNF and no colectomy.  
Results Four hundred and seventy-three CD and 189 UC were included (median follow-up: 13 and 11 years 
respectively). At 1 year, 147 patients had mild CD. At 5 years and the maximum follow-up, 56% and 13% 
patients still had mild CD, respectively. At 1 year, 142 patients had mild UC. At 5 years and the maximum 
follow-up, 72% and 44% still had a mild UC, respectively. Factors associated with long-term mild CD and UC 
were older age at diagnosis and absence of corticosteroids in the first year. In UC proctitis location was 
associated with mild UC.  
Conclusions In this cohort, 90% of CD patients and 3/4 of UC with mild disease at 1 year lost their mild disease 
status over time. An old age at diagnosis was predictive of the persistence of a mild CD and UC. 
 




Crohn's disease (CD) and ulcerative colitis (UC) are potentially progressive diseases characterised by the 
occurrence of complications leading to irreversible tissue damages.[1,2] The aim of CD and UC treatments is not 
only to induce a corticosteroid-free remission, but also to achieve mucosal healing to change the evolution of the 
disease. Immunomodulators (IMs) and particularly anti-TNFs are effective to induce mucosal healing in 
inflammatory bowel diseases (IBD). Patients should be stratified according to their individual risk to be offered 
the best treatment strategy. Potential aggressive IBD must be detected at diagnosis to start effective treatment 
before the occurrence of complications. Predictive factors of severe and disabling disease have been 
identified.[3,4] However, intensive therapies are not required in every patient. Predicting patients with persistent 
mild disease would be useful to avoid overtreatment associated with side effects and high costs. Mild IBD has 
never been clearly defined. Few data are available for the prevalence and the factors associated with long-term 
mild IBD.[5] The primary objective of our study was to describe the evolution of mild IBD and to identify 
demographic and clinical factors at diagnosis associated with the persistence of a mild IBD over the time. The 
secondary objective was to describe the clinical significance and the factors associated with a mild IBD 1 year 
after the diagnosis. 
Patients and methods  
Patients 
All patients with a complete follow-up reviewed in the IBD clinic of the CHU hospital of Liège in the last 3 
years were considered for inclusion. The diagnosis of CD and UC was based on standard criteria.[6] Disease 
location and behaviour were determined according to Montreal classification.[7] A minimum follow-up of 5 
years was required for inclusion. 
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Definition of mild CD 
Mild CD was defined as an inflammatory luminal CD without strictures, abdominal or perianal fistulae, 
requiring no IM or anti-TNF and no surgery over the course of the disease. 
Definition of mild UC 
Mild UC was defined by the absence of IM, anti-TNF or surgery over the course of the disease. 
Study design 
Retrospective analysis of the evolution of mild CD and UC defined 1 year after the diagnosis. Demographic 
factors including age, sex, smoking habits were recorded at diagnosis. Disease characteristics including location 
and behaviour were recorded, 1 year after the diagnosis, 5 years after the diagnosis and at the maximum follow-
up. Medical treatments, including corticosteroids, 5-aminosalicylates (5ASA), IM (thiopurines and methotrexate) 
and anti-TNF (infliximab, adalimumab, certolizumab), surgeries and hospitalisation for active IBD were 
recorded 1 year after the diagnosis, 5 years after the diagnosis and at the maximum follow-up. 
Definition of corticosteroids during the first year 
Only systemic corticosteroids were considered as treatment with corticosteroids during the first year. Topical 
corticosteroids, including suppositories and enema, oral budesonide and oral beclomethasone dipropionate were 
not considered as corticosteroid intake during the first year. 
Statistical analysis 
Descriptive statistics are expressed as mean (standard deviation) for continuous variables and as numbers 
(percentages) for qualitative variables. A logistic regression analysis was applied to test the association of 
demographic and clinical factors with mild IBD within the first year and with mild disease at maximum follow-
up, the odds ratio and 95% confidence intervals are provided. Multivariate logistic regression analysis was done 
on variables for which p was less than 0.10 in univariate analysis. The loss of mild disease status is represented 
by a Kaplan-Meier curve. A Cox regression analysis was used to evaluate the persistence of mild CD or UC with 
respect to predictive factors. Results were considered to be significant at the 5% confidence level (p<0.05). 
Calculations were done in SAS version 9.3 (SAS Institute, Cary, NC). 
 
Results 
Patients' recruitment and characteristics 
A total of 887 patients were screened for inclusion. Those without a definite diagnosis of CD or UC with 
incomplete data during follow-up or who did not meet the criteria of 5 years follow-up were excluded. The 
follow-up reported in the study describes all the events since the diagnosis of the patients till the last available 
follow-up after 5 years of evolution. We identified 473 CD patients and 189 UC patients suitable for the study. 
The median follow-up was 13 years (range: 8-22) and 11 years (range: 7-17) for CD and UC, respectively. 
In the CD patients, 147/473 (31%) had a mild CD at 1 year according to the definition (Figure 1). Inflammatory, 
stricturing and penetrating CD 1 year after the diagnosis were observed in 329/473 (69%), 89/473 (19%) and 
55/473 (12%) of the patients, respectively. Perianal lesions 1 year after the diagnosis were reported in 119/473 
patients (25%). 5ASA, IM and anti-TNF were given during the first year after the diagnosis, respectively, in 
319/473 (67%), 104/473 (20%) and 38/ 473 (8%) of the patients. In patients with available data corticosteroids 
were administrated during the first year after diagnosis in 97/184 patients (53%). Hospitalisation and surgery for 
active CD during the first year occurred in 133/225 (59%) and 89/473 (19%) patients, respectively. 
In the UC patients, 142/189 (75%) had a mild UC 1 year after the diagnosis according to the definition (Figure 
1). 5ASA, IM and anti-TNF were given during the first year after the diagnosis, respectively, in 168/189 (89%), 
16/189 (8%) and 3/189 (2%) of the patients. Corticosteroids were administrated during the first year after the 
diagnosis in 37/96 (39%); 21/73 (29%) and 6/189 (3%) patients were, respectively, hospitalised and operated for 
active UC during the first year after the diagnosis. Patients' characteristics are described in Table 1. 
Factors associated with mild IBD at 7 year 
In univariate analysis, mild CD 1 year after the diagnosis was associated with the absence of corticosteroids 
intake in the first year (66% vs. 40%, p = 0.008, OR = 2.31, 95% CI = 1.25-4.29), and with 5ASA intake in the 
first year (96% vs. 86%, p = 0.012, OR = 3.52, 95% CI = 1.33-9.32). The multivariate analysis did not consider 
corticosteroids (data available in 184/473 patients) intake and hospitalisation (data available in 225/473 patients) 
because of incomplete data. No factor was significant in the multivariate analysis (Table 2). 
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In UC, univariate analysis demonstrated that mild UC at 1 year was associated with the absence of corticosteroid 
intake in the first year (90% vs. 24%, p < 0.0001, OR = 8.13, 95% CI = 2.99-22.2), the absence of hospitalisation 
for active UC in the first year (67% vs. 33%, p = 0.0002, OR =10.2, 95% CI = 3.0-34.5), proctitis at 1 year (p = 
0.0002, vs. rectosigmoiditis: OR = 3.1, 95% CI = 0.65-14.5; vs. pancolitis: OR =12.5, 95% CI = 2.7-58.8). The 
multivariate analysis did not consider corticosteroids intake (data available in 96/189 patients) and 
hospitalisation (data available in 73/189 patients) because of incomplete data. In multivariate analysis, no factor 
was statistically predictive of mild UC at 1 year (Table 2). 
 
Figure 1. Patients recruitment. 
 
 
Table 1. Patients'characteristics. 
Patients characteristics CD, n = 473 (%) UC, n = 189 (%) 
Male gender 159 (34) 84 (44) 
Age at diagnosis (median, range) 24 (7-69) 33 (10-78) 
Disease duration in years (median, range) 13 (8-22) 11 (7-17) 
Age at diagnosis (Montreal)   
   A1 47 (10) 10 (5) 
   A2 361 (76) 119 (63) 
   A3 65 (14) 60 (32) 
CD location   
   L1 198 (42)  
   L2 80 (17)  
   L3 192 (41)  
CD behaviour at 1 year   
   B1 329 (69)  
   B2 89 (19)  
   B3 55 (12)  
Perianal disease at 1 year 119 (25)  
UC extend at 1 year   
   E1  46 (24) 
   E2  88 (47) 
   E3  53 (28) 
Active smoker 163 (34) 24 (12) 
Hospitalisation during the first year 133/225 (59) 21/73 (29) 
Surgery during the first year 89 (19) 6 (3) 
CS during the first year 97/184 (53) 37/96 (39) 
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5ASA during the first year 319 (67) 168 (89) 
IM during the first year 104 (20) 16 (8) 




Table 2. Factors associated with mild CD and UC 1 year after diagnosis. 
Factors p Value OR (95%CI) 
CD   
5ASA intake* p = 0.012 3.52 (1.33-9.32) 
No CS intake p = 0.008 2.31 (1.25-4.29) 
UC   
Location* p = 0.001 3.1 (0.65-14.5) 
E1 vs. E2 p = 0.001 12.5 (2.7-58.8) 
E1 vs. E3 p = 0.0002 10.2 (3.0-34.5) 
No hospitalisation* p < 0.0001 8.13 (2.99-22.2) 
No CS intake*   
*univariate. 
 
Evolution of mild CD beyond 1 year 
Among the 147 patients having mild CD 1 year after the diagnosis, 83/147 (56%) still had mild CD 5 years after 
the diagnosis (Figure 2). At 5 years, 11/147 (7%), 9/147 (6%) and 16/147 (11%) developed a stricturing, 
penetrating and perianal CD, respectively. Abdominal surgery was performed in 20/147 patients (14%). IM and 
anti-TNF were required in 36/147 (25%) and 16/147 (11%), respectively (Figure 3). At the maximum follow-up 
(median follow-up = 13 years), 19/147 (13%) patients had a mild CD (Figure 2): 51/147 (28%) developed 
strictures, 30/147 (17%) developed fistulae, 55/147 (31%) developed perianal lesions. Abdominal surgery was 
performed in 78/147 patients (43%). IM and anti-TNF were required in 126/147 (70%) and 90/147 (50%), 
respectively (Figure 4). The median time for CD worsening (loss of mild disease status) is illustrated in Table 3. 
The Kaplan-Meier curve of the loss of mild CD is shown in Figure 5. 
In univariate analysis, an older age at diagnosis either expressed as a continuous variable (p = 0.0005, OR = 
1.06, 95% CI: 1.02-1.09) or as categories according to Montreal classification (A2 or A3 vs. A1: p = 0.011, OR 
= 3.23, 95% CI: 1.31-7.94) was associated with long-term mild CD. The absence of corticosteroids intake during 
the first year after diagnosis was also associated with a mild CD in the long term (p = 0.0084, OR = 3.33). In 
multivariate analysis, no factors remained associated with mild disease evolution. 
Among patients with mild CD 1 year after the diagnosis factors associated with the persistence of mild CD over 
the time were analysed. In univariate analysis, the persistence of mild CD was associated with an older age at 
diagnosis either expressed as a continuous variable (p = 0.006, HR= 1.022, 95% CI: 1.01-1.04) or as categories 
according to Montreal classification (A2 or A3 vs. A1: p = 0.034, HR= 1.57, 95% CI: 1.03-2.37) (Table 4). In 
multivariate analysis, no factors remained associated the persistence of mild CD in this sub-group. 
 
Figure 2. Evolution of patients with mild IBD 1 year and 5 years after the diagnosis and at the maximum follow-
up. 
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Figure 3. Mode of CD worsening 5 years after the diagnosis. The different events causing the loss of the mild 
character of the disease are represented in the figure. Five years after the diagnosis, few patients experienced 




Figure 4. Mode of CD worsening at the maximum follow-up. The different events causing the loss of the mild 
character of the disease are represented in the figure. The complications leading to tissue damage increased 
compared to the evolution after 5 years. More than half of the patients were treated with IM and/or anti-TNF at 
the maximum follow-up. 
 
 
Figure 5. Survey with mild CD. Among the 147 patients with mild CD 1 year after the diagnosis 80% of the 
patients had mild CD 10 years after the diagnosis and 40% 20 years after the diagnosis. After a longer period of 
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Table 3. Median time for loss of mild CD status. 
Events inducing loss of mild CD status Months (IQR) 
Stricturing disease 98 (55-180) 
Fistulising disease 89 (34-174) 
Perianal disease 89 (48-138) 
Surgery 91 (48-169) 
IS 72 (23-132) 
Anti-TNF 89 (26-163) 
 
Table 4. Factors associated with persistence of mild IBD in patients with mild IBD at 1 year. 
Factors p Value HR (95% CI) 
CD   
   Older age at diagnosis* p = 0.006 1.022 (1.01-1.04) 
   Montreal A1* p = 0.034 1.57 (1.03-2.37) 
UC   
   Older age at diagnosis* p = 0.006 1.022 (1.01-1.04) 
*univariate. 
 
Table 5. Median time from diagnosis to UC worsening. 
Characteristic UC of worsening Months (IQR) 
IS 54 (4-449) 
Anti-TNF 69 (3-245) 
Surgery 125 (24-480) 
 
Figure 6. Mode of UC worsening 5 years after the diagnosis. The different events causing the loss of the mild 
character of the disease are represented in the figure. Only 2% of the patients required surgery. 
Immunomodulators and anti-TNF were prescribed in 23% and 9% of the patients, respectively. 
 
 
Figure 7. Mode of UC worsening at maximum follow-up. The different events causing the loss of the mild 
character of the disease are represented in the figure. Only 15% of the UC patients required surgery. 
Immunomodulators and anti-TNF were prescribed in 54% and 31% of the patients, respectively. 
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Figure 8. Survey with mild UC. Among the 142 patients with mild UC 1 year after the diagnosis still 80% of the 
patients had mild CD 10 years after the diagnosis and 40% 20 years after the diagnosis. After a longer period of 
time there is a trend for a progressive loss of the mild character of the UC but the curve seems to reach a plateau. 
 
 
Evolution of mild UC beyond 1 year 
Among the 142 patients having mild UC 1 year after the diagnosis, 102/142 (72%) still had mild UC 5 years 
after the diagnosis (Figure 2). At 5 years, abdominal surgery was performed in 3/142 patients (2%). IM and anti-
TNF were required in 33/142 (23%) and 13/142 (9%), respectively (Figure 6). At the maximum follow-up 
(median follow-up = 11 years) 62/142 (44%) patients had a mild UC (Figure 2). Surgery was performed in 
21/142 patients (15%). IM and anti-TNF were required in 76/142 (54%) and 44/142 (31%), respectively (Figure 
7). The median time to loss of mild disease status is illustrated in Table 5. The Kalpan-Meier curve of loss of 
mild UC is shown in Figure 8. 
In univariate analysis, no demographic factors were associated with mild UC. The disease characteristics at 1 
year associated with mild UC in the long term were the rectal location (p = 0.01, proctitis vs. rectosigmoiditis: 
OR: 2.02, 95% CI = 0.97-4.2; proctitis vs. pancolitis: OR = 3.85, 95% CI = 1.6-9.3) and the absence of 
corticosteroids intake during the first year (p = 0.004, OR = 3.32, 95% CI = 1.46-7.58). No factor was 
significantly associated with mild UC in the multivariate analysis. 
Among patients with mild UC 1 year after the diagnosis factors associated with the persistence of mild CD over 
the time were analysed. In univariate analysis, only older age at diagnosis was associated with the persistence of 
mild UC over the time (p = 0.006, HR = 1.022, 95% CI = 1.01 -1.04) (Table 4). 
 
Discussion 
The present study suggests that about one-third of CD and three quarters of UC had a mild IBD defined 1 year 
after diagnosis. A few CD patients (12%) still had a mild CD over the long term, while about 50% of UC 
patients still had a mild disease after a long follow-up period. In addition, the study shows that an older age at 
diagnostic was predictive of the persistence of a mild CD and UC over the time. 
This is the first study proposing a definition of mild CD and mild UC and looking for its persistence over time. 
For both diseases, we used a strict definition including the absence of irreversible tissue damages: absence of 
stricture, fistulae, perianal lesions, surgery in CD, absence of surgery in UC. In CD, Pariente et al. [1] 
demonstrated that time could lead to complications and additive digestive damages. This accumulation is 
suspected to progressively impair the intestinal function and the quality of life.[8] Active chronic UC can also 
induce a loss of colonic function [2] and an increased risk of colonic cancer.[9] Our definition of mild CD and 
UC also excluded the requirement of IM or anti-TNF in the course of the disease because they are usually 
associated with a worsening of the disease and with an increased incidence of infectious [10-12] and oncologic 
complications.[13,14] 
We described a 44%-rate of UC patients having a persisting mild disease over the long term which is consistent 
with the previous data.[15,16] However, the 90% rate of non-mild CD at the maximum follow-up is probably 
largely overestimated. Two independent reference centre studies [3,4] assessed the outcome of disabling CD at 5 
years. The definition of disabling CD was close to the opposite of our mild disease definition. Only 20-40% of 
the patients did not have a disabling CD at 5 years compared to 17% in our cohort. In population-based studies, 
however, about 50% of the patients remained complications free at 5 years.[17] The initial 3 years following 
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diagnosis were the more active and some degree of disease extinction was observed over time. In addition, few 
patients with a low disease activity during the first year experienced a significant worsening of the disease over 
time.[17] In our study, a large proportion of mild CD at 1 year finally did not meet the criteria of mild disease 
over the time. This is in contradiction with the concept of disease extinction suggested in previously published 
population-based study [17] and may indicate a recruitment bias: the patients with initial mild disease we 
recruited are precisely those who lost this mild disease status and were then referred to our centre. 
The characteristics of the disease worsening must also be taken into account. At 5 years only 7%, 6% and 11% 
experienced strictures, fistulae, perianal lesions, respectively, and only 17%, 28% and 31%, respectively, at the 
maximum follow-up (median 16 years). Except for perianal lesions,[18-20] the rates of stricturing and 
penetrating disease were lower in this population of mild CD at 1 year than in the global CD population 
previously described. According to our definition, a large proportion of patients lost the mild character of the 
disease because of the introduction of IM (70%) or anti-TNF (50%). This treatment strategy may reflect an 
aggressive course of the disease but also a strategy of optimised step-up based on close monitoring of the 
patients. An argument for this hypothesis is the increased incidence of non-mild disease in most recent patients, 
probably reflecting an evolution in the treatment strategy over the last two decades. Surgery had to be performed 
in 43% of the CD patients after more than 15 years of follow-up. Solberg et al. [17] reported 38% of surgery 
after 10 years. The findings from our referral centre are close to the results of this Norwegian population-based 
cohort taking into account the longer follow-up in our cohort. This can reflect a strategy of optimised step-up 
treatment strategy leading to less complication rates and less surgery. Although similar, our results cannot be 
strictly compared with those from the IBSEN study because this is not a population-based study but a 
monocentre retrospective cohort. The population-based cohort of Rungoe et al. [21] demonstrated a decreased 
probability rate of surgery at 5 years in CD and UC in the last 10 years but without a surgery-sparing effect of 
newer medications. Due to the retrospective character of the study, the type of resection was not taken into 
account. A short ileal resection for stricturing disease can be associated with a favourable disease outcome, while 
a long ileal resection or any colonic resection is usually associated with severe disease and functional bowel 
impairment. Thus, some surgeries in our cohort can be associated with good clinical outcome despite our 
definition of non-mild disease in the present study. Few patients with UC underwent surgery in our study (15%). 
Recent population-based studies reported that approximately 10% of patients with UC will require colectomy 
after 10 years.[22,23] A recent study reported a need of colectomy of 7.5%, 10.4% and 14.8%, respectively, at 5, 
10 and 20 years after the diagnosis.[24] A significant number of colectomies occurred in the first year of the 
disease and during the first hospitalisation for UC. Elective colectomy rates have significantly decreased in the 
last decade and alongside the use of purine and anti-TNF increased in UC suggesting a better control of the 
disease with the medications.[24] In our cohort, 47% and 27% of the patients required finally IM and anti-TNF, 
respectively. 
The existence of a mild CD 1 year after the diagnosis was associated with the absence of the use of 
corticosteroids and the use of 5ASA in the first year reflecting a milder disease course. The initial need for 
corticosteroids has already been identified as a predictor of a disabling and severe disease [3,4] and as a predictor 
of complication in non-complicated CD at diagnosis.[25] 
An older age at diagnosis was associated with a benign evolution of CD and with the persistence of mild CD in 
the group of patients having a mild CD at 1 year. Our findings confirm the results from the Saint-Antoine cohort 
in Paris [5] that demonstrated an association of this factor with mild to moderate CD. Consistently, the reverse 
was observed for young age at diagnosis, which has been associated with a severe course of the disease.[3,4] 
Disease location had no impact on the overall outcome of CD throughout the long-term follow-up of our cohort. 
This confirms again the Saint-Antoine results, while Loly et al. [4] found a significant association with more 
extensive CD and disabling disease. 
We demonstrated that mild UC 1 year after the diagnosis and in the long term was associated with proctitis at 1 
year. Lower rate of hospitalisation and corticosteroids use was associated with mild UC 1 year after the 
diagnosis, reflecting as in CD a milder disease course. The only factor associated with persistence of mild 
disease over time in the group of patients with mild UC at 1 year was an older age at diagnosis. This factor has 
already been associated with a less severe UC [22,26,27] but the issue of these studies was the need for 
colectomy. Our work confirms this mild outcome also taking into account the need for IM and anti-TNF. 
Our study has several limitations. First because of the retrospective character of the study potentially associated 
with incomplete data and follow-up we only selected recently reviewed patients with complete follow-up of 
minimum 5 years. This can induce a bias by selecting more severe patient requiring a regular follow-up. Because 
of the retrospective character of the study we obtained incomplete data on the CS use in the first year and the 
hospitalisation rate during the first year and had to exclude them in the multivariate analysis although there were 
significant in the univariate analysis. Second, our population is a referral centre-based cohort probably including 
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more severe patients with higher rates of complications, surgery and a higher need for IM and anti-TNF 
compared to population-based studies. This recruitment bias may underestimate the number of patients with mild 
IBD. In our cohort, the number of CD patients is higher than the number of UC patients reflecting a higher 
prevalence of CD than UC in our region.[28]. Third, due to the retrospective character of the study, the type of 
surgery was not taken into account. A short ileal resection for stricturing disease can be associated with a 
favourable disease outcome in opposite to long ileal resection or any colonic resection associated with severe 
disease and functional bowel impairment. Thus, some surgeries in our cohort can be associated with good 
clinical outcome despite our definition of non-mild disease in the present study. 
In conclusion, only a small minority of CD patients but up to half of the UC patients followed up in a referral 
centre have persisting mild disease over time. Apart from an older age at diagnosis, no other factor was 
predictive of persisting mild CD and UC. This suggests a prudent step-up approach in older patients, while a 
close monitoring is probably the most appropriate option in younger patients, particularly in CD to avoid the 
overtreatment and reduce a significant economic burden due to biological and immunosuppressive therapy. 
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